More evidence on Saxenda's impact in weight loss
Danish diabetes company Novo Nordisk (NOV: N) has provided further proof that its therapies are not just of benefit to diabetics by presenting new evidence on the effect of Saxenda (liraglutide 3mg) in weight management.
Use of the glucagon-like peptide-1 (GLP-1) brought an average of 8.1kg after six months in a real-world clinical setting, in combination with diet and exercise, according to data presented this week at the European Congress on Obesity (ECO 2018) in Austria and the Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research in Baltimore, USA.
The retrospective effectiveness study investigated the impact of Saxenda treatment in people with overweight and obesity across six weight management clinics in Canada.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze